Amplitude Surgical – H1 2020-21

Sales down 5.3% at Constant Exchange Rates

Regulatory News:

Amplitude Surgical (ISIN: FR0012789667, Ticker: AMPLI, eligible for PEA-PME plans) (“Amplitude” or the “Group”)  (Paris:AMPLI), leading French player on the global surgical technology market for lower-limb orthopedics, announces its sales for the first half of its 2020-21 financial year.

Olivier Jallabert, Amplitude Surgical’s CEO, commented: “In the first half of our 2020-21 financial year, Amplitude Surgical’s activity was impacted, in the second quarter, by the deterioration in the public health situation associated with COVID-19 on the majority of its markets and by the adoption of restrictions on access to operating rooms. As a result, the Group’s activity was down by 5.3% at constant exchange rates compared with the previous year. Novastep has continued its development, and now accounts for approximately 13% of Group sales, with growth of almost 25% at constant exchange rates. Despite the COVID-19 impact, the Group is in a solid financial position and intends to seize any external growth opportunities by looking into openings to acquire rival companies or agents”.

H1 2020-21 sales	6 months to 31/12/2020	6 months to 31/12/2019	Change at current exchange rates	Change at constant exchange rates
In €k - IFRS
France	29,615	30,404	-2.6%	-2.6%
International	16,295	19,429	-16.1%	-9.6%
o/w subsidiaries	12,457	14,363	-13.3%	-4.4%
o/w distributors	3,839	5,066	-24.2%	-24.3%
Total	45,910	49,833	-7.9%	-5.3%